Navigation Links
FDA Wants New Diabetes Drugs Tested for Heart Risks
Date:12/17/2008

Companies must now show their drugs don't increase chances of cardiac trouble

WEDNESDAY, Dec. 17 (HealthDay News) -- The U.S. Food and Drug Administration is now asking all companies looking for approval of new type 2 diabetes medications to undertake studies that determine whether they cause cardiovascular problems.

This new guidance document, announced Wednesday, comes on the heels of reports that two commonly prescribed blood sugar-lowering drugs already on the market, Avandia and Actos, increase the risk of heart failure and, in the case of Avandia, increase the risk of heart attack.

"The guidance document will help industry evaluate the cardiovascular risk associated with new therapies under development to treat type 2 diabetes," Dr. Mary Parks, director of the Division of Metabolism and Endocrinology Products in FDA's Center for Drug Evaluation and Research said during a Wednesday afternoon teleconference.

Parks noted that diabetic patients are already at an increased risk for cardiovascular problems. But the agency believes it's important to insure that new drugs don't compound the risk further, she said. More than 23 million people in the United States have been diagnosed with type 2 diabetes.

The new guidance reflects the decision of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which in July called for studies of the cardiovascular risks of new diabetic drugs.

According to the new guidance, companies looking to have new diabetes drugs approved by the FDA must submit data from phase II and phase III trials that show these drugs are not associated with an "unacceptable risk" of cardiovascular disease, Parks said.

Parks noted that these new requirements mean that companies will have to enroll more patients in clinical trails than in the past, especially more older patients who are already at risk for heart disease.

Trials assessing cardiovascular risks will have to go on for at least a year, Parks said. "The trials have to be of an adequate duration so that we can get a sense of long-term risk," she explained.

The change in the approval process does mean that it will take longer for new drugs to reach the market. "It's safe to assume that requiring a longer duration of trials, and a bolstering of the sample size, that it will add some years to the clinical development program," Parks said.

The FDA has sent 100 to 150 letters to companies with new diabetes products under development to alert them of the new guidance, which takes effect immediately, Parks said.

This guidance document does not affect drugs already on the market. These drugs will be the subject of another guidance document, Parks said. When that document will be released isn't known. "It's on our to-do list," she said.

More information

For more information on diabetes, visit the U.S. National Institute on Diabetes and Kidney Diseases .



SOURCES: Dec. 17, 2008, teleconference with Mary Parks, M.D., director, Division of Metabolism and Endocrinology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Poll Shows Public Worried About Medicare Cuts Impact on Seniors, Boomers - Wants Congress To Act
2. Adverse housing conditions contribute to diabetes risk
3. RAND finds cases of undiagnosed diabetes drop sharply
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Diabetes appears to increase risk of death for patients with acute coronary syndromes
6. Discovery of sugar sensor in intestine could benefit diabetes
7. Despite overeating, morbidly obese mice gain protection against diabetes
8. Heart Attack Boosts Diabetes Risk
9. Obesity Doesnt Always Equal Diabetes
10. Sugary Sodas High in Diabetes-Linked Compound
11. Treating diabetes during pregnancy can break link to childhood obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Wants New Diabetes Drugs Tested for Heart Risks
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... ... student scholarship will be awarded for the fall semester to a deserving student. ... Emergency Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon ... for a unique opportunity that helps high school girls succeed in STEM programs ... Opportunities.” Horizon Goodwill will host over 20 high school girls at their ...
(Date:7/24/2017)... ... 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host a ... (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy Suites ... will run from 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. ...
(Date:7/24/2017)... ... 24, 2017 , ... The Topricin Companies, formerly Topical Biomedics, ... revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. , ... skin conditions, including cancer. In the short term, overexposure to sun, wind ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... fat (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 ... its adipose filtration technology. The '398 and '324 patents cover methods and ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... -- Centurion Medical Products, a leader in medical product innovation and global ... device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a hospice,s ... while preventing unneeded emergency department admission due to severe fecal impaction. ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... 11, 2017  Bayer has awarded grants totaling more than ... of its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. ... Philadelphia and Uniformed Services University of the Health ... winners. Grant recipients were announced last night during a reception ... Congress, Berlin, Germany . ...
Breaking Medicine Technology: